Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of BioCentury, Week in Review: Sales and Marketing

BioCentury, Week in Review Current Issue
  • Quest Diagnostics, Beth Israel Deaconess Medical Center (BIDMC), Weill Cornell Medical College sales and marketing update

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Beth Israel Deaconess Medical Center (BIDMC), Boston, Mass. Weill Cornell Medical College, New York, N.Y. Business: Diagnostic Quest launched a molecular blood test in …

    Published on 3/26/2012
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer Roche launched Zelboraf vemurafenib in the U.K. to treat unresectable or metastatic melanoma in patients with BRAF V600 mutations. The European …

    Published on 3/26/2012
  • Almirall, GW Pharma sales and marketing update

    Almirall S.A. (Madrid:ALM), Barcelona, Spain GW Pharmaceuticals plc (LSE:GWP), Salisbury, U.K. Business: Musculoskeletal Almirall and GW added Mexico to a 2005 deal granting Almirall exclusive marketing rights to …

    Published on 3/19/2012
  • BioDelivery sales and marketing update

    BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Business: Neurology BioDelivery said the U.S. relaunch of pain drug Onsolis fentanyl is being postponed so that two appearance issues raised by FDA …

    Published on 3/19/2012
  • MorphoSys sales and marketing update

    MorphoSys AG (Xetra:MOR), Martinsried, Germany Business: Diagnostic MorphoSys said a HuCAL antibody from its AbD Serotec division was included for use in an undisclosed supplier's diagnostic test related to maternal …

    Published on 3/19/2012
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Inflammation Takeda's Nycomed unit launched Omnaris ciclesonide nasal spray in the United Arab Emirates to treat allergic rhinitis in patients over the…

    Published on 3/19/2012
  • 20/20 GeneSystems sales and marketing update

    20/20 GeneSystems Inc., Rockville, Md. Business: Diagnostic 20/20's Genesys BioLabs division launched PAULA's blood test for the early detection of lung cancer. The test scores patients' risk of lung cancer based on …

    Published on 3/12/2012
  • Abbott sales and marketing update

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Pharmaceuticals Abbott's Starlims Corp. company acquired five of its distribution partners. The acquisitions included Varilab, two undisclosed private Spanish …

    Published on 3/12/2012
  • Altogen Biosystems Inc. sales and marketing update

    Altogen Biosystems Inc., Las Vegas, Nev. Business: Supply/Service Altogen launched its Pancreas-targeted siRNA In Vivo RNAi Transfection Kit worldwide for use in laboratories and research facilities. The liposome-based …

    Published on 3/12/2012
  • Boehringer Ingelheim, Eli Lilly sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co.(NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic Boehringer Ingelheim and partner Eli Lilly launched Jentadueto linagliptin/metformin in the U.S…

    Published on 3/12/2012
  • Cornerstone Therapeutics, Merus Labs International sales and marketing update

    Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Merus Labs International Inc. (TSX:MLI; NASDAQ:MSLI), Toronto, Ontario Business: Infectious Merus acquired North American rights to Factive gemifloxacin mesylate …

    Published on 3/12/2012
  • diaDexus sales and marketing update

    diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic diaDexus launched its PLAC Test in Europe to measure lipoprotein-associated phospholipase A2 (Lp-PLA2) as an aid to assess the risk for …

    Published on 3/12/2012
  • Dr. Reddy's, Pfizer sales and marketing update

    Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Neurology, Generics Dr. Reddy's launched a generic version of Pfizer's Geodon ziprasidone in the U.S. to treat …

    Published on 3/12/2012
  • Horizon Pharma, Mundipharma sales and marketing update

    Horizon Pharma Inc. (NASDAQ:HZNP), Deerfield, Ill. Mundipharma International Ltd., Cambridge, U.K. Business: Autoimmune The companies added 17 territories to their 2010 deal granting Mundipharma exclusive rights to …

    Published on 3/12/2012
  • Illumina sales and marketing update

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Business: Genomics Illuminasaid its TruSeqAmplicon - Cancer Panel to detect somatic mutations is available for order and will begin shipping worldwide next month. The panel…

    Published on 3/12/2012
  • KingMed, Qiagen sales and marketing update

    KingMed Diagnostics, Guangzhou, China Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands Business: Diagnostic Qiagen and KingMed will co-market Qiagen's Digene HPV test in China. Qiagen, which said partnering …

    Published on 3/12/2012
  • Leo Pharma sales and marketing update

    Leo Pharma A/S, Ballerup, Denmark Business: Autoimmune Leo Pharma's Leo Pharma Inc. subsidiary said that last November it launched a patient assistant program for its Taclonex ointment and Taclonex Scalp topical …

    Published on 3/12/2012
  • Mela Sciences sales and marketing update

    Mela Sciences Inc. (NASDAQ:MELA), Irvington, N.Y. Business: Diagnostic Mela Sciences launched MelaFind in the U.S. and Germany to aid in the detection of melanoma. MelaFind is a computer-controlled tool that identifies …

    Published on 3/12/2012
  • Pfizer, Ranbaxy sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359), Gurgaon, India Business: Endocrine/Metabolic Ranbaxy launched a generic version of cholesterol therapy Lipitor atorvastatin in …

    Published on 3/12/2012
  • Qiagen sales and marketing update

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands Business: Diagnostic Qiagen's Ipsogen S.A. subsidiary launched its NPM1 MutaScreen worldwide to determine nucleophosmin (NPM1; B23) mutation status in …

    Published on 3/12/2012
  • Simcere sales and marketing update

    Simcere Pharmaceutical Group (NYSE:SCR), Nanjing, China Business: Autoimmune Simcere disclosed in its 4Q11 earnings that during 1Q12 it launched Iremod iguratimod to treat rheumatoid arthritis (RA) in China. China's …

    Published on 3/12/2012
  • Systagenix sales and marketing update

    SystagenixWound Management Ltd., Crawley, U.K. Business: Dermatology In January, Systagenix launched WOUNDCHEK Protease Status in Europe, the Middle East and Africa to detect elevated protease activity (EPA) in chronic …

    Published on 3/12/2012
  • Teva, Watson, Abbott sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), Petah Tikva, Israel Watson Pharmaceuticals Inc. (NYSE:WPI), Parsippany, N.J. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Genitourinary, Generics Teva …

    Published on 3/12/2012
  • Sanofi sales and marketing update

    Sanofi(Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Sanofi's Genzyme Corp. unit said it began shipping Fabry's disease therapyFabrazymeagalsidase beta manufactured at its newly approved …

    Published on 3/5/2012
  • ViroPharma sales and marketing update

    ViroPharma Inc. (NASDAQ:VPHM), Exton, Pa. Business: Cardiovascular ViroPharma launched Cinryze in the U.K. for the treatment and pre-procedure prevention of acute attacks of hereditary angioedema (HAE) in adolescents …

    Published on 3/5/2012

< Previous   1  2  3  4  5  6  7  8  9  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Catalent

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?